Vaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62%

GuruFocus.com12-18

Following breaching minimal listing criteria, Vaccinex (VCNX, Financials) will be delisted from Nasdaq, the firm said. As the company negotiates clinical trial developments and financial challenges, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492629939?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/P3USSRknj54CkoonZHgmKA--~B/aD05ODU7dz0yMTI3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/8b34282df3e337e017d4d48d8d2bb143","is_english":true,"pubTime":"2024-12-18 00:06","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2492629939","market":"us","top_or_hot":-1,"title":"Vaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62%","media":"GuruFocus.com","content":"<div>\n<p>Following breaching minimal listing criteria, Vaccinex (VCNX, Financials) will be delisted from Nasdaq, the firm said. As the company negotiates clinical trial developments and financial challenges, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/vaccinex-faces-nasdaq-delisting-amid-160614658.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 00:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/vaccinex-faces-nasdaq-delisting-amid-160614658.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Following breaching minimal listing criteria, Vaccinex (VCNX, Financials) will be delisted from Nasdaq, the firm said. As the company negotiates clinical trial developments and financial challenges, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/vaccinex-faces-nasdaq-delisting-amid-160614658.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QLD","symbol_name":"纳指两倍做多ETF","start_time":0,"source_url":"https://finance.yahoo.com/news/vaccinex-faces-nasdaq-delisting-amid-160614658.html","article_id":"2492629939","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/P3USSRknj54CkoonZHgmKA--~B/aD05ODU7dz0yMTI3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/8b34282df3e337e017d4d48d8d2bb143"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492629939","pubTimestamp":1734451574,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Following breaching minimal listing criteria, Vaccinex  will be delisted from Nasdaq, the firm said. As the company negotiates clinical trial developments and financial challenges, shares dropped 62.6% to settle at $1.36 on last look.According to Nasdaq Listing Rule 5550, Vaccinex was warned on December 16, 2024, that its shares will be delisted for non-compliance with its equity requirement of $2.5 million. Offically stopping on December 18, 2024, at market open, Vaccinex intends its shares to move to the OTC Markets Group with the current symbol VCNX.With a cash balance of $5.2 million in its most recent quarterly statement, the delisting draws attention to the mounting financial strain the Rochester, N.Y.-based biotechnology company reports. As Vaccinex advances its main treatment, pepinemab, throughout many clinical studies, losses have increased.Vaccinex, with headquarters in Rochester, New York, focuses on treatments for malignancies and neurological illnesses. Targeting semaphor","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"QLD":"纳指两倍做多ETF","BK4585":"ETF&股票定投概念","NVIW.SI":"NVDA 3xLongSG261006","BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SQQQ":"纳指三倍做空ETF","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4568":"美国抗疫概念",".IXIC":"NASDAQ Composite","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","USJW.SI":"ALPHAB 3xLongSG261006","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","QID":"纳指两倍做空ETF","TSYW.SI":"TESLA 3xLongSG261006","USAW.SI":"AMZN 3xLongSG261006","BK4112":"金融交易所和数据","TQQQ":"纳指三倍做多ETF","VCNX":"Vaccinex Inc.","PSQ":"纳指反向ETF"},"translate_title":"Vaccinex因财务困境面临纳斯达克退市；股价下跌62%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":1,".IXIC":1,"VCNX":0.9,"USJW.SI":0.6,"USAW.SI":0.6,"TSYW.SI":0.6,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NVIW.SI":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"Following breaching minimal listing criteria, Vaccinex (VCNX, Financials) will be delisted from Nasdaq, the firm said. As the company negotiates clinical trial developments and financial challenges, shares dropped 62.6% to settle at $1.36 on last look.\n\nWarning! GuruFocus has detected 5 Warning Signs with VCNX.\n\nAccording to Nasdaq Listing Rule 5550(b), Vaccinex was warned on December 16, 2024, that its shares will be delisted for non-compliance with its equity requirement of $2.5 million. Offically stopping on December 18, 2024, at market open, Vaccinex intends its shares to move to the OTC Markets Group with the current symbol VCNX.\nWith a cash balance of $5.2 million in its most recent quarterly statement, the delisting draws attention to the mounting financial strain the Rochester, N.Y.-based biotechnology company reports. As Vaccinex advances its main treatment, pepinemab, throughout many clinical studies, losses have increased.\nVaccinex, with headquarters in Rochester, New York, focuses on treatments for malignancies and neurological illnesses. Targeting semaphorin 4D (SEMA4D), a protein associated to inflammatory pathways in brain diseases and immune system inhibition in malignancies, pepinemab, its main medication candidate, acts.\nCiting good pre-clinical data in immune-oncology settings, Vaccinex is also looking into possible licencing agreements and alliances to hasten the development of pepinemab.\nDriven by rising R&D expenses, the company's net losses in financial terms expanded to $14.3 million in its latest stated quarter. Vaccinex stressed, however, its emphasis on progressing its main medication candidate and discussed strategic actions to increase liquidity.\nRetaining worldwide commercial rights to pepinemab, Vaccinex presents a possible major benefit for combination treatments in cancer and chronic brain illnesses.This article first appeared on \nGuruFocus.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492629939"}